Leslie M. Shaw, Ph.D.
Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Director, Alzheimer's Disease Neuroimaging, Initiative Biomarker Core Laboratory, University of Pennsylvania
Department: Pathology and Laboratory Medicine
Contact information
Hospital of the University of Pennsylvania
7.103 Founders Pavilion 3400 Spruce Street
Philadelphia, PA 19104
7.103 Founders Pavilion 3400 Spruce Street
Philadelphia, PA 19104
Office: (215) 662-6575
Fax: (215) 662-7529
Fax: (215) 662-7529
Education:
B.S. (Cum Laude, Chemistry)
LeMoyne College, Syracuse, New York, 1962.
Ph.D. (Biochemistry)
S.U.N.Y. at Upstate Medical Center, 1968.
Permanent linkB.S. (Cum Laude, Chemistry)
LeMoyne College, Syracuse, New York, 1962.
Ph.D. (Biochemistry)
S.U.N.Y. at Upstate Medical Center, 1968.
Description of Research Expertise
Development, validation and implementation of neurodegenerative diseases biomarkers in cerebrospinal fluid and plasma into treatment trials and clinical studies (eg, ADNI study; UPENN ADRC; PPMI study). These studies include the use of manual and highly automated immunoassays and for amyloid beta(1-42), U-p53AZ and for total tau the use of high sensitivity UPLC/tandem mass spectrometry. Multi-modal statistical analyses of these study data to address several questions including the diagnostic utilities of these biomarkers; assessments of the longitudinal trajectories of these biomarkers in AD, MCI and cognitively normal controls to assess the neuropathological changes over time in these individuals.Description of Clinical Expertise
Measurement and interpretation of the toxicokinetics of drugs and toxins in patients affected by them. Interpretation of the pharmacokinetics of immunosuppressant maintenance medications in transplant patients.Description of Other Expertise
Development and implementation of mass spectrometry-based methods for measuring small molecules of clinical utility including therapeutic drugs, toxins and special chemistry tests including Xylazine; 25-OH vitamin D; and biologicals, eg, Infliximab. Development, validation and implementation of plasma based Alzheimers Disease biomarkers.Selected Publications
Cousins KAQ, Irwin DJ, Tropea TF, Rhodes E, Phillips JS, Chen-Plotkin AS, Brumm MC, Coffey CS, Kang JH, Simuni T, Foroud T, Toga AW, Tanner CM, Kieburtz K, Mollenhauer B, Galasko DR, Hutten S, Weintraub D, Tiderowf AS, Marek K, Kollmorgen G, Poston KL, Shaw LM, The Parkinson’s Progression Marker Initiative.: Evaluation of ATNPD framework and biofluid markers to predict cognitive decline in early Parkinson’s Disease. Neurology. In Press 2024. In Press.Bonomi S, Lu R, Schindler SE, Bui Q, Lah JJ, Wolk D, Gleason CE, Sperling R, Roberson ED, Levey AI, Shaw L, Van Hulle C, Benzinger T, Adams M, Manzanares C, Qiu D, Hassentab J, Moulder KL, Balls-Berry JE, Johnson K, Johnson SC, Murchison CF, Luo J, Gremminger E, Agboola F, Grant EA, Hornbeck R, Massoumzadeh P, Keefe S, Dierker D, Gray J, Henson RL, Streitz M, Mechanic-Hamilton D, Morris JC, Xiong C.: Relationships of cognitive measures with cerebrospinal fluid but not imaging biomarkers of Alzheimer Disease vary between black and white individuals. Ann Neurol. 95: 495-50. 2024.
Shaw LM, Korecka M, Lee EB, Cousins KAQ, Vanderstichele H, Schindler SE, Tosun D, DeMarco ML, Brylska M, Wan Y, Burnham S, Sciulli A, Vulaj A, Tropea TF, Chen-Plotkin A, Wolk DA, for the Alzheimer’s Disease Neuroimaging Initiative*. : ADNI Biomarker Core: A Review of Progress Since 2004 and Future Challenges. Alz. Dementia. In Press 2024, in Press.
Xiong C, Luo J, Wolk DA, Shaw LM, Roberson ED, Murchison CF, Henson RL, Benzinger TLS, Bui Q, Agboola F, Grant E, Gremminger E, Moulder KL, Geldmacher DS, Clay OJ, Babulal G, Cruchaga C, Holtzman DM, Bateman RJ, Morris JC, Schindler SE. : Baseline levels and longitudinal changes in plasma Aβ42/40 among Black/African American and White individuals. Nat. Communic, 2024 - In Press.
Tosun D, Hausle Z, Iwaki H, Thropp P, Lamoureux J, Lee EB, MacLeod K, McEvoy S, Nalls M, Perrin RJ, Saykin AJ, Shaw LM, Singleton AB, Lebovitz R, Weiner MW, Blauwendraat C, for the Alzheimer’s Disease Neuroimaging Initiative. : A cross-sectional study of α-synuclein seed amplification assay in Alzheimer’s disease neuroimaging initiative: Prevalence and associations with Alzheimer’s Disease biomarkers and cognitive function. Alz. Dementia. In Press. 2024 - In Press.
Schindler SE, Petersen KK, Saef B, Tosun D, Shaw LM, Zetterberg H, Dage JL, Ferber K, Triana-Baltzer G, Du-Cuny L, Li Y, Coomaraswamy J, Baratta M, Mordashova Y, Saad ZS, Raunig DL, Ashton NJ, Meyers EA, Rubel CE, Rosenbaugh EG, Bannon AW, Potter WZ, Alzheimer’s Disease Neuroimaging Initiative (ADNI)**, Foundation for the National Institutes of Health (FNIH).: Biomarkers Consortium Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer’s Disease Project Team. Head-to-head comparison of leading blood tests for Alzheimer’s disease pathology. MedRxiv Pre-print. 2024 Notes: doi.org/10.1101/2024.06.12.24308839.
Hampel H, Hu Y, Cummings J, Mattke S, Iwatsubo T, Nakamura A, Vellas B, O’Bryant S, Shaw LM, Cho M, Batrla R, Vergallo A, Blennow K, Dage J, Suzanne E. Schindler.: Blood-based biomarkers for Alzheimer’s disease: current state and future use in a transformed global healthcare landscape. Neuron. 111(18): 2781-2799, 09 2023
Shaw LM, Galasko D. : Assessments of the utilities of CSF NPTX2 for disease progression in cognitively normal individuals who progress to clinical MCI and AD. Ann Neurol. Editorial - Invited Commentary. 94(4): 618-19, Oct 2023.
Baldaranov D, Garcia V, Miller G, Donohue MC, Shaw LM, Weiner M, Petersen RC, Aisen P, Raman R, Rafii MS. : Safety and tolerability of lumbar puncture for the evaluation of Alzheimer's disease. Alzheimer's Dement (Amst). 18(15 (2)): e12431, Apr 2023.
Tropea TF, Waligorska T, Xie SX, Nasrallah IM, Cousins KAQ, Trojanowski JQ, Grossman M, Irwin DJ, Weintraub D, Lee EB, Wolk DA, Chen-Plotkin AS, Shaw LM; Alzheimer's Disease Neuroimaging Initiative. : Plasma phosphorylated tau181 predicts cognitive and functional decline. Ann Clin Transl Neurol. 10(1): 18-31, Jan. 2023 Notes: doi: 10.1002/acn3.51695. Epub 2022 Dec 14.